Related Experiment Video
Updated: Apr 16, 2026
05:39
Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination
Published on: February 9, 2021
3.8K
MT1-MMP-Targeted Photoimmunotherapy via an IR700-Conjugated Bicyclic Peptide.
Naoya Kondo1, Takuya Otani1, Ayaka Kanai1
1Division of Fundamental Technology Development, Near InfraRed Photo-immunoTherapy Research Institute, Kansai Medical University, 2-5-1 Shin-machi, Hirakata, Osaka 573-1010, Japan.
Bioconjugate Chemistry
|April 15, 2026
Summary
A novel nonantibody photoimmunotherapy (PIT) agent targeting MT1-MMP was developed. This peptide-dye conjugate effectively destroyed cancer cells in vitro and inhibited tumor growth in vivo, offering a promising alternative to current antibody-based PIT treatments.
Area of Science:
- Oncology
- Biochemistry
- Photomedicine
Background:
- Current antibody-based photoimmunotherapy (PIT) agents are costly and cleared slowly.
- There is a need for alternative scaffolds for effective PIT.
Purpose of the Study:
- To develop and evaluate a nonantibody scaffold for PIT using a bicyclic peptide targeting membrane-type 1 matrix metalloproteinase (MT1-MMP).
- To assess the efficacy of this novel agent in vitro and in vivo.
Main Methods:
- Chemical synthesis and characterization of a bicyclic peptide conjugated to IRDye700DX (bcMT1-IR700).
- In vitro studies using HT1080 (MT1-MMP-overexpressing) and A549 (MT1-MMP-low) cells with 690 nm irradiation.
- In vivo studies involving HT1080 xenografts in mice following intravenous administration and tumor irradiation.
Main Results:
- bcMT1-IR700 demonstrated selective binding and cytotoxicity in MT1-MMP-overexpressing cells in vitro.
- The agent accumulated rapidly in tumors and was primarily cleared renally in vivo.
- Tumor-directed irradiation significantly inhibited tumor growth in xenograft models.
Conclusions:
- MT1-MMP-targeted bicyclic peptide-mediated PIT is a viable nonantibody alternative.
- Further optimization of dosing, illumination, and testing in immunocompetent models is warranted to define its full therapeutic potential.
